Nuvectis Pharma, Inc.
SEC CIK 1875558 · NVCT · last insider filing 2026-06-12
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Oliviero James F III | Director | filed 2022 - 2026 |
| Hoberman Kenneth | Director | filed 2022 - 2026 |
| Kaplan Matthew L. | Director | filed 2022 - 2026 |
| Sanchez Juan | Director | filed 2025 - 2026 |
| Bentsur RON | Director · Chairman & CEO | filed 2022 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Shemesh Shay | Chief Development Officer | filed 2022 - 2026 |
| Carson Michael J. | Vice President, Finance | filed 2022 - 2026 |
| Poradosu Enrique | Chief Science and Business Off | filed 2022 - 2026 |
| Ben-Or Uri | Int. Principal Financial Off. | filed 2022 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.